1. Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting 
G. Catho, S. Couraud, S. Grard, A. Bouaziz, A. Sénéchal, F. Valour, T. Perpoint, E. Braun, F. Biron, T. Ferry, C. Chidiac, N. Freymond, E. Perrot, P.-J. Souquet, J.-M. Maury, F. Tronc, N. Veziris, G. Lina, O. Dumitrescu, F. Ader 
Clinical Microbiology and Infection 
Volume 21, Issue 5, Pages 472.e7-472.e10 (May 2015)
DOI: /j.cmi
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Summary of multidrug-resistant (MDR) tuberculosis (TB) patients who achieved intensive and continuation phases with the recommended number of drugs, and the current status of ongoing treatments (the intensive phase lasted for 8 months, and the continuation phase lasted for 12 months). AMK, amikacin.
Clinical Microbiology and Infection  , 472.e7-472.e10DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions